Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.910
-0.010 (-0.34%)
At close: Aug 4, 2025, 4:00 PM
2.860
-0.050 (-1.72%)
After-hours: Aug 4, 2025, 5:03 PM EDT
Blueprint Medicines Employees
As of March 31, 2025, Vistagen Therapeutics had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 17 or 42.50% compared to the previous year.
Employees
57
Change (1Y)
17
Growth (1Y)
42.50%
Revenue / Employee
$8,526
Profits / Employee
-$902,070
Market Cap
84.85M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 57 | 17 | 42.50% |
Mar 31, 2024 | 40 | 6 | 17.65% |
Mar 31, 2023 | 34 | -2 | -5.56% |
Mar 31, 2022 | 36 | 15 | 71.43% |
Mar 31, 2021 | 21 | 12 | 133.33% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VTGN News
- 4 days ago - Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 - Business Wire
- 11 days ago - Vistagen to Present at the BTIG Virtual Biotechnology Conference - Business Wire
- 20 days ago - Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership - Business Wire
- 5 weeks ago - Vistagen Appoints Elissa Cote as Chief Corporate Development Officer - Business Wire
- 6 weeks ago - Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 7 weeks ago - Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 - Business Wire
- 2 months ago - Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year - Business Wire